Mikart, LLC, contract development and manufacturing organization (CDMO) has completed a new liquids and suspensions suite in Atlanta, GA. The investment is in response to clients’ demand to provide expert contract services to develop robust, reliable liquid dosage forms. Mikart’s clients now have access to a variety of temperature controlled tanks that support a wide diversity of volumes ranging from 4,000L to 50L to volumes. This investment further supports our growing geriatric and pediatric product development and manufacturing capabilities.

The facility suite will be capable of manufacturing complex suspension products, including extended release products.

“The new capabilities enhance our support of early to late-stage formulation development, enabling clients to quickly scale-up to GMP manufacture of clinical trial materials,” said Michael Kallelis, CEO at Mikart. “This added capability will expedite the development process and further differentiate Mikart’s CDMO services in the small molecule space.”

Gus LaBella, director of formulation development at Mikart, said, “Manufacturing suspensions can be quite difficult on a large scale. Mikart has performed extensive testing in this suite and the adjacent packaging area to ensure product quality is maintained from start to finish.”

Nazar Elkarim, vice president of product development Services at Mikart, said, “We continue to see strong demand for liquid and suspension products across several indications. These investments will enable us to expand our capabilities, and offer greater agility for our customers.”